multiple sclerosis
FDA approves first three generic versions of Novartis’ Gilenya for relapsing multiple sclerosis
December 6, 2019Medical Communications, Sales and Marketing Novartis, generics, gilenya, multiple sclerosis, pharma
The FDA has approved the first three generic versions of Novartis’ sphingosine 1-phosphate receptor modulator Gilenya (fingolimod) to treat adult …
EMA advisory panel recommends Mayzent for secondary progressive multiple sclerosis
November 18, 2019Sales and Marketing Europe, Mayzent, Novartis, multiple sclerosis, pharma
Novartis has revealed that Mayzent (siponimod) has been recommended by the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
FDA approves Biogen and Alkermes’ Vumerity for relapsing multiple sclerosis
October 30, 2019Research and Development, Sales and Marketing Alkermes, Biogen, FDA, Vumerity, multiple sclerosis, pharma
The FDA has given the green light to Vumerity (diroximel fumarate), a novel oral fumarate developed by Biogen and Alkermes, …
Novartis announce robust Phase 3 trials for ofatumumab in MS
September 16, 2019Research and Development, Sales and Marketing Aubagio, Novartis, multiple sclerosis
Novartis’ multiple sclerosis candidate has demonstrated strong results in its Phase 3 ASCLEPIOS trials meeting primary endpoints and slashing the …
Multi-study data confirms Ocrevus’ long-term efficacy in reducing disability progression in multiple sclerosis
September 13, 2019Medical Communications, Research and Development ECTRIMS, Ocrevus, Roche, multiple sclerosis, pharma
Roche has taken the opportunity at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference in Stockholm …
Novartis’ Mayzent delays time wheelchair dependence by 4 years in secondary progressive multiple sclerosis
September 12, 2019Research and Development ECTRIMS 2019, Mayzent, Novartis, multiple sclerosis, pharma
Novartis has taken the opportunity at the 2019 Congress of The European Committee for Treatment and Research in Multiple Sclerosis …
Decade-long data support Biogen’s Tecfidera in relapsing multiple sclerosis
September 11, 2019Research and Development Biogen, multiple sclerosis, pharma, tecfidera
Biogen has revealed new long-term data for Tecfidera (dimethyl fumarate), reinforcing the benefits of the therapy over a decade-long period …
Sandoz acquires global commercialisation rights to Polpharma’s multiple sclerosis biosimilar
September 3, 2019Manufacturing and Production, Sales and Marketing Polpharma, Sandoz, biosimilar, multiple sclerosis, pharma
Sandoz has revealed that it has sealed a deal with Polpharma Biologics to commercialise the latter’s proposed biosimilar version of …
Novartis’ ofatumumab outclasses Sanofi’s Aubagio at Phase 3 in relapsing multiple sclerosis
September 3, 2019Manufacturing and Production, Research and Development Arzerra, Genmab, Novartis, multiple sclerosis, pharma
New data from two Phase 3 studies have indicated that Novartis’ ofatumumab outperformed Sanofi Genzyme’s Aubagio (teriflunomide) in the treatment …
Genmab & Novartis’ ofatumumab tops Sanofi’s Aubagio in relapsing multiple sclerosis
August 30, 2019Medical Communications, Research and Development Genmab, Novartis, multiple sclerosis, ofatumumab, pharma
Genmab and Novartis have revealed positive new data from two Phase 3 studies of its monthly subcutaneous formulation of ofatumumab …
Biogen & Alkermes’ multiple sclerosis drug proves “statistically superior” to Tecfidera at Phase 3
July 31, 2019Research and Development Alkermes, Biogen, multiple sclerosis, pharma
Biogen and Alkermes have unveiled new Phase 3 data for diroximel fumarate, comparing the adequacy of the therapy to Biogen’s …
J&J’s ponesimod meets primary and secondary endpoints at Phase 3 in relapsing multiple sclerosis
July 26, 2019Medical Communications, Research and Development Johnson & Johnson, multiple sclerosis, pharma, ponesimod
New Phase 3 data has been released on Johnson & Johnson’s selective sphingosine-1-phosphate receptor 1 (S1P1) modulator ponesimod, reporting that …
MRI scans can help predict MS patient’s long term prognosis, 15 year study shows
July 25, 2019Research and Development CIS, MRI scans, MS, Prognosis, diagnosis, multiple sclerosis, pharma
MRI scans can predict MS patient’s long term prognosis when they are first diagnosed, according to new research. In a …
A decade after US approval, Novartis’ Gilenya scores marketing authorisation in China for relapsing multiple sclerosis
July 19, 2019Medical Communications, Sales and Marketing Novartis, gilenya, multiple sclerosis, pharma
Novartis has revealed that its disease modifying drug Gilenya (fingolimod) has secured approval in China for the treatment of relapsing …
Biogen’s diroximel fumarate impresses at Phase 3 in relapsing multiple sclerosis
May 31, 2019Medical Communications, Research and Development Biogen, diroximel fumarate, multiple sclerosis, pharma, relapsingg multiple sclerosis
New data for Biogen’s investigational therapy diroximel fumarate has been revealed at the Consortium of Multiple Sclerosis Centers (CMSC) in …
